Discover a groundbreaking webinar delving into the advancements in AI and digitization in precision pathology and image analysis applications in the pharmaceutical, chemical and biotech industries. Although the pioneers started more than 20 years ago, digital and quantitative precision pathology is now coming to age and is especially maturing in diagnostic human pathology, including artificial intelligence (AI)-assisted diagnosis. In development in the pharma sector — and less so in early research, the field was lagging behind, due to a combination of factors, one of them being the very rigorous regulatory framework in place for safety studies and the other being the high throughput with usually low input data of highly demanding large study format.
However, in recent years, the COVID-19 pandemic has elicited big strides in the progress of executing safety, biodistribution and pharmacology studies digitally locally or remotely, and the sector is evolving with unprecedented speed. In parallel, computer capabilities and AI sectors have steeply expanded to reach practical empowerment.
This webinar will review the various milestones in AI and digitization in precision pathology in the industry and show the audience the rapid adoption in the contract research organization arena and where the challenges currently are. It will help newcomers as well as experts better understand where the chemistry, pharma and biotech industries are and want to go.
Join this webinar to gain insights into an overview of the advancements in AI and image analysis (AI/IA) applications and AI and digitization in precision pathology to aid in drug discovery in the pharma, chemical and biotech sectors, with concrete examples and perspectives from a pathology-centered, tissue-based, mid-sized clinical research organization (CRO).
Dr. Thomas Lemarchand, DVM, DESV-AP, PhD, DECVP, Director, Digital & Quantitative Pathology, StageBio
Thomas Lemarchand is a European College of Veterinary Pathology board-certified French Toxicologic, Experimental and Comparative Pathologist with 30 years of experience. Thomas started his career as a diagnostician and research Immuno-Pathologist in the United States and received his PhD from Louisiana State University in 2000.
He then joined the biopharmaceutical industry in Europe as a Research and Regulatory Safety Pathologist in Servier then Eli Lilly & Company. Thomas moved to contract research organizations in 2007 to develop tissue cross-reactivity and immunohistochemistry/in situ hybridization assays and has contributed to hundreds of studies.
Thomas is currently embracing and leading the digital revolution in pathology at StageBio and specializes in in situ molecular techniques and investigative/efficacy studies in animal models out of TPL Path Labs GmbH, a StageBio company, based in Freiburg, Germany. Thomas helps clients design the best possible clinical and non-clinical efficacy or safety investigative studies and is leading the implementation of in situ molecular assays and quantitative pathology projects with specialized image analysis, along with performing pathology evaluations.
Derick Vollmer, Digital Pathology Manager, StageBio
Derick Vollmer has been working in imaging and image analysis at StageBio for over 10 years. He started with StageBio as an Imaging Specialist, followed by his role as a Morphometrist for many years and now manages their digital pathology initiatives while still performing various imaging and image analysis tasks alongside their growing team.
Who Should Attend?
This webinar will appeal to professionals in the following areas:
- Research Scientists, Toxicologists, Pathologists and Lab Managers in pharma/biotechnology
- Clinical R&D Scientists, MD Pharmacists and Principal Investigators in clinical research
- Anyone interested in spatial biology and precision pathology in research and diagnosis
- Computer IT, Imaging Scientists, Image Analysts and Specialists
- Drug hunters in general
What You Will Learn
Attendees will gain insights into:
- The key milestones in the digital implementation of pathology within the chemistry, pharma and biotech industries
- The current status and future directions of digital pathology in chemistry, pharmaceuticals and biotechnology
- The potential of digital pathology in diagnosing common lesions in toxicology studies, leveraging AI to assist pathologists in distinguishing treated animals from control groups
- How digital pathology enables reproducible lesion quantification and assessment of morphological changes in tissue lesions
- An overview of current image management systems used in the industry
- The array of available AI systems for image analysis (IA) and their applications in pharmaceutical and biotech research and development
StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities in the U.S., along with one GLP laboratory in Europe. We will continue to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more at stagebio.com.